

Venue:

Zanhotel Europa, via Cesare Boldrini 11- Bologna

Target Audience:

The event will be included in the Continuing Medical Education (CME) program for the following professions and specialties: **Medical Doctors (MD)** with specialization in Hematology, Oncology, Internal Medicine; Biologists; Biotechnologists.

Registration:

For information: info@centercongressi.com

NPM1 AND r-KMT2A LEUKEMIAS:

PRESENT AND FUTURE

27

OCTOBER
2026

Bologna

ZANHOTEL EUROPA

VIA CESARE BOLDRINI, 11



NPM1 AND r-KMT2A LEUKEMIAS:

PRESENT AND FUTURE

27
OCTOBER
2026

Bologna

ZANHOTEL EUROPA
VIA CESARE BOLDRINI, 11

Rationale

The meeting “NPM1 and r-KMT2A Leukemias: Present and Future” is designed as an advanced scientific forum focused on two biologically and clinically distinct subtypes of acute myeloid leukemia (AML), characterized by NPM1 mutations and KMT2A rearrangements. These entities represent paradigmatic models of molecularly defined AML, in which genomic and epigenetic alterations drive leukemogenesis and are increasingly informing therapeutic development.

The primary objective of the meeting is to provide an updated and integrated overview of disease biology, molecular classification, and evolving targeted treatment strategies, highlighting how emerging discoveries are reshaping risk assessment and clinical decision-making.

The program aims to stimulate in-depth discussion among experts on pathogenetic mechanisms, innovative diagnostic tools, measurable residual disease assessment, and patient fitness evaluation. Particular attention will be devoted to epigenetic regulation in AML, including the therapeutic implications of menin inhibition and the role of hypomethylating agents such as oral decitabine within both low-intensity and combinatorial treatment strategies.

By fostering a strong translational perspective, the meeting seeks to bridge laboratory research and real-world clinical practice, ultimately supporting more refined risk stratification and the development of increasingly personalized treatment pathways for patients affected by these AML subtypes.

Scientific Coordinator:

- Cristina Papayannidis,
Hematologist at Institute of Hematology and Medical Oncology, Bologna University

Faculty

- M. Annunziata, *Napoli*
- L. Brunetti, *Ancona*
- P. Chiusolo, *Roma*
- D. Cilloni, *Torino*
- A. Curti, *Bologna*
- M. Gottardi, *Treviso*
- F. Grimaldi, *Napoli*
- B. Izzo, *Napoli*
- M. W.M. Kühn, *Mainz, Germany*
- G. Marconi, *Ravenna*
- M.P. Martelli, *Perugia*
- J. Nanni, *Bologna*
- E. Ottaviani, *Bologna*
- R. Palmieri, *Roma*
- C. Papayannidis, *Bologna*
- A. Hernandez Sanchez, *Salamanca – Spagna*
- C. Sartor, *Bologna*
- C. Skert, *Mestre*

8.00 Registration

8.30 Welcome and aim of the meeting
Antonio Curti, Cristina Papayannidis

SESSION I: BIOLOGY OF NPM1 AND R-KMT2A LEUKEMIAS *D. Cilloni, M. P. Martelli*

9.00 Understanding disease biology in NPM1 mutated AML: what's new?
L. Brunetti

9.20 NPM1+ AML: the role of co-mutations in risk stratification
A. Hernandez Sanchez

9.40 CD33: beyond a surface marker
G. Marconi

10.00 New diagnostics pannels in AML
E. Ottaviani

10.20 Discussion

11.00 Coffee break

11.20 Lecture: Targeting KMT2A: Menin complex in leukemia
Michael W.M. Kühn

SESSION II: CURRENT APPROACHES TO NPM1 AND R-KMT2A LEUKEMIAS *P. Chiusolo, M. Gottardi*

11.40 Fitness assessment in AML: beyond chronological age
R. Palmieri

12.00 NPM1+ AML: the role of GO in the frontline fit patients setting
Antonio Curti

12.20 Targeting NPM1+ and r-KMT2A: Menin inhibitors update
Cristina Papayannidis

12.40 Menin Inhibition: future strategies
Michael W.M. Kühn

13.00 Clinical case
J. Nanni

13.20 Discussion

14.00 Light Lunch

SESSION III: FUTURE PERSPECTIVES *M. Annunziata, C. Skert*

15.00 Novel epigenetic strategies in AML: the role of oral decitabine
F. Grimaldi

15.20 New molecular targets for menin inhibition: diagnostics implications
B. Izzo

15.40 MRD driven strategy in NPM1+ AML: state of the art
C. Sartor

16.00 Discussion

16.20 Take home messages

16.30 Test and “Arrivederci”